A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Study Of BTRX-246040 Administered Once Daily In Patients With Major Depressive Disorder With Or Without Anhedonia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2018
At a glance
- Drugs BTRX 246040 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors BlackThorn Therapeutics
- 11 Sep 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 11 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018.
- 11 Sep 2018 Status changed from recruiting to active, no longer recruiting.